Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program
Publication
, Conference
Shen, Q; Xu-Monette, ZY; Manyam, G; Visco, C; Tzankov, A; Cao, X; Deng, L; Montes-Moreno, S; Dybkaer, K; Chiu, A; Orazi, A; Zu, Y; Bhagat, G ...
Published in: BLOOD
December 6, 2014
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Shen, Q., Xu-Monette, Z. Y., Manyam, G., Visco, C., Tzankov, A., Cao, X., … Young, K. H. (2014). Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. In BLOOD (Vol. 124). San Francisco, CA: AMER SOC HEMATOLOGY.
Shen, Qi, Zijun Yidan Xu-Monette, Ganiraju Manyam, Carlo Visco, Alexander Tzankov, Xin Cao, Lijuan Deng, et al. “Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.
Shen Q, Xu-Monette ZY, Manyam G, Visco C, Tzankov A, Cao X, et al. Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. In: BLOOD. AMER SOC HEMATOLOGY; 2014.
Shen, Qi, et al. “Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.
Shen Q, Xu-Monette ZY, Manyam G, Visco C, Tzankov A, Cao X, Deng L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi W, Van Krieken JHJM, Huh J, Ponzoni M, Ferreri AJM, Farnen JP, Moller MB, Winter JN, Piris MAA, Medeiros LJ, Young KH. Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program. BLOOD. AMER SOC HEMATOLOGY; 2014.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology